

Adalimumab, Infliximab And Etanercept Biosimilars Market - Global Outlook and Forecast 2021-2027

<https://marketpublishers.com/r/A015DBBC02F7EN.html>

Date: April 2021

Pages: 107

Price: US\$ 3,250.00 (Single User License)

ID: A015DBBC02F7EN

Abstracts

This report contains market size and forecasts of Adalimumab, Infliximab And Etanercept Biosimilars in global, including the following market information:

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Revenue, 2016-2021, 2022-2027, (\$ millions)

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Sales, 2016-2021, 2022-2027, (K Units)

Global top five Adalimumab, Infliximab And Etanercept Biosimilars companies in 2020 (%)

The global Adalimumab, Infliximab And Etanercept Biosimilars market was valued at xx million in 2020 and is projected to reach US\$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adalimumab, Infliximab And Etanercept Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Adalimumab, Infliximab And Etanercept Biosimilars Market, By Type, 2016-2021, 2022-2027 (\$ Millions) & (K Units)

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, By Type, 2020 (%)

Adalimumab Biosimilars

Infliximab Biosimilars

Etanercept Biosimilars

Global Adalimumab, Infliximab And Etanercept Biosimilars Market, By Application, 2016-2021, 2022-2027 (\$ Millions) & (K Units)

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, By Application, 2020 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Adalimumab, Infliximab And Etanercept Biosimilars Market, By Region and Country, 2016-2021, 2022-2027 (\$ Millions) & (K Units)

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, By Region and Country, 2020 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Adalimumab, Infliximab And Etanercept Biosimilars revenues in global market, 2016-2021 (Estimated), (\$ millions)

Key companies Adalimumab, Infliximab And Etanercept Biosimilars revenues share in global market, 2020 (%)

Key companies Adalimumab, Infliximab And Etanercept Biosimilars sales in global market, 2016-2021 (Estimated), (K Units)

Key companies Adalimumab, Infliximab And Etanercept Biosimilars sales share in global market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

Boehringer Ingelheim

Abbvie

Cipla Ltd

Hetero Drugs Limited

Pfizer

Novartis

Samsung Bioepis(Samsung Biologics)

Amgen

Celltrion Healthcare

Mylan

HETERO

Glenmark Pharmaceuticals

Emcure Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Neutropenia Biologic Drug Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Drug Type
 - 1.2.2 Market by Application
- 1.3 Global Neutropenia Biologic Drug Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUTROPENIA BIOLOGIC DRUG TREATMENT OVERALL MARKET SIZE

- 2.1 Global Neutropenia Biologic Drug Treatment Market Size: 2021 VS 2027
- 2.2 Global Neutropenia Biologic Drug Treatment Revenue, Prospects & Forecasts: 2016-2027
- 2.3 Global Neutropenia Biologic Drug Treatment Sales (Consumption): 2016-2027

3 COMPANY LANDSCAPE

- 3.1 Top Neutropenia Biologic Drug Treatment Players in Global Market
- 3.2 Top Global Neutropenia Biologic Drug Treatment Companies Ranked by Revenue
- 3.3 Global Neutropenia Biologic Drug Treatment Revenue by Companies
- 3.4 Global Neutropenia Biologic Drug Treatment Sales by Companies
- 3.5 Global Neutropenia Biologic Drug Treatment Price by Manufacturer (2016-2021)
- 3.6 Top 3 and Top 5 Neutropenia Biologic Drug Treatment Companies in Global Market, by Revenue in 2020
- 3.7 Global Manufacturers Neutropenia Biologic Drug Treatment Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Neutropenia Biologic Drug Treatment Players in Global Market
 - 3.8.1 List of Global Tier 1 Neutropenia Biologic Drug Treatment Companies
 - 3.8.2 List of Global Tier 2 and Tier 3 Neutropenia Biologic Drug Treatment Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Global Neutropenia Biologic Drug Treatment Market Size Markets, 2021 & 2027

4.1.2 Filgrastim

4.1.3 Pegfilgrastim

4.1.4 Lenograstim

4.1.5 Lipegfilgrastim

4.1.6 Sargramostim

4.2 By Type - Global Neutropenia Biologic Drug Treatment Revenue & Forecasts

4.2.1 By Type - Global Neutropenia Biologic Drug Treatment Revenue, 2016-2021

4.2.2 By Type - Global Neutropenia Biologic Drug Treatment Revenue, 2022-2027

4.2.3 By Type - Global Neutropenia Biologic Drug Treatment Revenue Market Share, 2016-2027

4.3 By Type - Global Neutropenia Biologic Drug Treatment Sales & Forecasts

4.3.1 By Type - Global Neutropenia Biologic Drug Treatment Sales, 2016-2021

4.3.2 By Type - Global Neutropenia Biologic Drug Treatment Sales, 2022-2027

4.3.3 By Type - Global Neutropenia Biologic Drug Treatment Sales Market Share, 2016-2027

4.4 By Type - Global Neutropenia Biologic Drug Treatment Price (Manufacturers Selling Prices), 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Neutropenia Biologic Drug Treatment Market Size, 2021 & 2027

5.1.2 Retail Pharmacies

5.1.3 Hospital Pharmacies

5.1.4 Online Pharmacies

5.2 By Application - Global Neutropenia Biologic Drug Treatment Revenue & Forecasts

5.2.1 By Application - Global Neutropenia Biologic Drug Treatment Revenue, 2016-2021

5.2.2 By Application - Global Neutropenia Biologic Drug Treatment Revenue, 2022-2027

5.2.3 By Application - Global Neutropenia Biologic Drug Treatment Revenue Market Share, 2016-2027

5.3 By Application - Global Neutropenia Biologic Drug Treatment Sales & Forecasts

- 5.3.1 By Application - Global Neutropenia Biologic Drug Treatment Sales, 2016-2021
- 5.3.2 By Application - Global Neutropenia Biologic Drug Treatment Sales, 2022-2027
- 5.3.3 By Application - Global Neutropenia Biologic Drug Treatment Sales Market Share, 2016-2027
- 5.4 By Application - Global Neutropenia Biologic Drug Treatment Price (Manufacturers Selling Prices), 2016-2027

6 SIGHTS BY REGION

- 6.1 By Region - Global Neutropenia Biologic Drug Treatment Market Size, 2021 & 2027
- 6.2 By Region - Global Neutropenia Biologic Drug Treatment Revenue & Forecasts
 - 6.2.1 By Region - Global Neutropenia Biologic Drug Treatment Revenue, 2016-2021
 - 6.2.2 By Region - Global Neutropenia Biologic Drug Treatment Revenue, 2022-2027
 - 6.2.3 By Region - Global Neutropenia Biologic Drug Treatment Revenue Market Share, 2016-2027
- 6.3 By Region - Global Neutropenia Biologic Drug Treatment Sales & Forecasts
 - 6.3.1 By Region - Global Neutropenia Biologic Drug Treatment Sales, 2016-2021
 - 6.3.2 By Region - Global Neutropenia Biologic Drug Treatment Sales, 2022-2027
 - 6.3.3 By Region - Global Neutropenia Biologic Drug Treatment Sales Market Share, 2016-2027
- 6.4 North America
 - 6.4.1 By Country - North America Neutropenia Biologic Drug Treatment Revenue, 2016-2027
 - 6.4.2 By Country - North America Neutropenia Biologic Drug Treatment Sales, 2016-2027
 - 6.4.3 US Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.4.4 Canada Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.4.5 Mexico Neutropenia Biologic Drug Treatment Market Size, 2016-2027
- 6.5 Europe
 - 6.5.1 By Country - Europe Neutropenia Biologic Drug Treatment Revenue, 2016-2027
 - 6.5.2 By Country - Europe Neutropenia Biologic Drug Treatment Sales, 2016-2027
 - 6.5.3 Germany Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.5.4 France Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.5.5 U.K. Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.5.6 Italy Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.5.7 Russia Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.5.8 Nordic Countries Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.5.9 Benelux Neutropenia Biologic Drug Treatment Market Size, 2016-2027
- 6.6 Asia

- 6.6.1 By Region - Asia Neutropenia Biologic Drug Treatment Revenue, 2016-2027
- 6.6.2 By Region - Asia Neutropenia Biologic Drug Treatment Sales, 2016-2027
- 6.6.3 China Neutropenia Biologic Drug Treatment Market Size, 2016-2027
- 6.6.4 Japan Neutropenia Biologic Drug Treatment Market Size, 2016-2027
- 6.6.5 South Korea Neutropenia Biologic Drug Treatment Market Size, 2016-2027
- 6.6.6 Southeast Asia Neutropenia Biologic Drug Treatment Market Size, 2016-2027
- 6.6.7 India Neutropenia Biologic Drug Treatment Market Size, 2016-2027
- 6.7 South America
 - 6.7.1 By Country - South America Neutropenia Biologic Drug Treatment Revenue, 2016-2027
 - 6.7.2 By Country - South America Neutropenia Biologic Drug Treatment Sales, 2016-2027
 - 6.7.3 Brazil Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.7.4 Argentina Neutropenia Biologic Drug Treatment Market Size, 2016-2027
- 6.8 Middle East & Africa
 - 6.8.1 By Country - Middle East & Africa Neutropenia Biologic Drug Treatment Revenue, 2016-2027
 - 6.8.2 By Country - Middle East & Africa Neutropenia Biologic Drug Treatment Sales, 2016-2027
 - 6.8.3 Turkey Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.8.4 Israel Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.8.5 Saudi Arabia Neutropenia Biologic Drug Treatment Market Size, 2016-2027
 - 6.8.6 UAE Neutropenia Biologic Drug Treatment Market Size, 2016-2027

7 MANUFACTURERS & BRANDS PROFILES

- 7.1 Amgen
 - 7.1.1 Amgen Corporate Summary
 - 7.1.2 Amgen Business Overview
 - 7.1.3 Amgen Neutropenia Biologic Drug Treatment Major Product Offerings
 - 7.1.4 Amgen Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)
 - 7.1.5 Amgen Key News
- 7.2 Novartis
 - 7.2.1 Novartis Corporate Summary
 - 7.2.2 Novartis Business Overview
 - 7.2.3 Novartis Neutropenia Biologic Drug Treatment Major Product Offerings
 - 7.2.4 Novartis Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)

7.2.5 Novartis Key News

7.3 Pfizer

7.3.1 Pfizer Corporate Summary

7.3.2 Pfizer Business Overview

7.3.3 Pfizer Neutropenia Biologic Drug Treatment Major Product Offerings

7.3.4 Pfizer Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)

7.3.5 Pfizer Key News

7.4 Baxter International

7.4.1 Baxter International Corporate Summary

7.4.2 Baxter International Business Overview

7.4.3 Baxter International Neutropenia Biologic Drug Treatment Major Product Offerings

7.4.4 Baxter International Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)

7.4.5 Baxter International Key News

7.5 Cellerant Therapeutics

7.5.1 Cellerant Therapeutics Corporate Summary

7.5.2 Cellerant Therapeutics Business Overview

7.5.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Major Product Offerings

7.5.4 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)

7.5.5 Cellerant Therapeutics Key News

7.6 Dong-A ST Co.,Ltd.

7.6.1 Dong-A ST Co.,Ltd. Corporate Summary

7.6.2 Dong-A ST Co.,Ltd. Business Overview

7.6.3 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Major Product Offerings

7.6.4 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)

7.6.5 Dong-A ST Co.,Ltd. Key News

7.7 Myelo Therapeutics GmbH

7.7.1 Myelo Therapeutics GmbH Corporate Summary

7.7.2 Myelo Therapeutics GmbH Business Overview

7.7.3 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Major Product Offerings

7.7.4 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)

- 7.7.5 Myelo Therapeutics GmbH Key News
- 7.8 Sanofi
 - 7.8.1 Sanofi Corporate Summary
 - 7.8.2 Sanofi Business Overview
 - 7.8.3 Sanofi Neutropenia Biologic Drug Treatment Major Product Offerings
 - 7.8.4 Sanofi Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)
 - 7.8.5 Sanofi Key News
- 7.9 Teva Pharmaceutical Industries Ltd.
 - 7.9.1 Teva Pharmaceutical Industries Ltd. Corporate Summary
 - 7.9.2 Teva Pharmaceutical Industries Ltd. Business Overview
 - 7.9.3 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Major Product Offerings
 - 7.9.4 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)
 - 7.9.5 Teva Pharmaceutical Industries Ltd. Key News
- 7.10 Kyowa Kirin
 - 7.10.1 Kyowa Kirin Corporate Summary
 - 7.10.2 Kyowa Kirin Business Overview
 - 7.10.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Major Product Offerings
 - 7.10.4 Kyowa Kirin Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)
 - 7.10.5 Kyowa Kirin Key News
- 7.11 CVS Health
 - 7.11.1 CVS Health Corporate Summary
 - 7.11.2 CVS Health Neutropenia Biologic Drug Treatment Business Overview
 - 7.11.3 CVS Health Neutropenia Biologic Drug Treatment Major Product Offerings
 - 7.11.4 CVS Health Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)
 - 7.11.5 CVS Health Key News
- 7.12 Partner Therapeutics
 - 7.12.1 Partner Therapeutics Corporate Summary
 - 7.12.2 Partner Therapeutics Neutropenia Biologic Drug Treatment Business Overview
 - 7.12.3 Partner Therapeutics Neutropenia Biologic Drug Treatment Major Product Offerings
 - 7.12.4 Partner Therapeutics Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)
 - 7.12.5 Partner Therapeutics Key News
- 7.13 Enzychem Lifesciences Corporation

- 7.13.1 Enzychem Lifesciences Corporation Corporate Summary
- 7.13.2 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Business Overview
- 7.13.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Major Product Offerings
- 7.13.4 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Sales and Revenue in Global (2016-2021)
- 7.13.5 Enzychem Lifesciences Corporation Key News

8 GLOBAL NEUTROPENIA BIOLOGIC DRUG TREATMENT PRODUCTION CAPACITY, ANALYSIS

- 8.1 Global Neutropenia Biologic Drug Treatment Production Capacity, 2016-2027
- 8.2 Neutropenia Biologic Drug Treatment Production Capacity of Key Manufacturers in Global Market
- 8.3 Global Neutropenia Biologic Drug Treatment Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

- 9.1 Market Opportunities & Trends
- 9.2 Market Drivers
- 9.3 Market Restraints

10 NEUTROPENIA BIOLOGIC DRUG TREATMENT SUPPLY CHAIN ANALYSIS

- 10.1 Neutropenia Biologic Drug Treatment Industry Value Chain
- 10.2 Neutropenia Biologic Drug Treatment Upstream Market
- 10.3 Neutropenia Biologic Drug Treatment Downstream and Clients
- 10.4 Marketing Channels Analysis
 - 10.4.1 Marketing Channels
 - 10.4.2 Neutropenia Biologic Drug Treatment Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

- 12.1 Note
- 12.2 Examples of Clients
- 12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Adalimumab, Infliximab And Etanercept Biosimilars in Global Market

Table 2. Top Adalimumab, Infliximab And Etanercept Biosimilars Players in Global Market, Ranking by Revenue (2019)

Table 3. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue by Companies, (US\$, Mn), 2016-2021

Table 4. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Share by Companies, 2016-2021

Table 5. Global Adalimumab, Infliximab And Etanercept Biosimilars Sales by Companies, (K Units), 2016-2021

Table 6. Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Share by Companies, 2016-2021

Table 7. Key Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Price (2016-2021) & (US\$/Unit)

Table 8. Global Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Product Type

Table 9. List of Global Tier 1 Adalimumab, Infliximab And Etanercept Biosimilars Companies, Revenue (US\$, Mn) in 2020 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Adalimumab, Infliximab And Etanercept Biosimilars Companies, Revenue (US\$, Mn) in 2020 and Market Share

Table 11. By Type – Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2021 VS 2027

Table 12. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2016-2021

Table 13. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2022-2027

Table 14. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2016-2021

Table 15. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2022-2027

Table 16. By Application – Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2021 VS 2027

Table 17. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2016-2021

Table 18. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars

Revenue (US\$, Mn), 2022-2027

Table 19. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2016-2021

Table 20. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2022-2027

Table 21. By Region – Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2021 VS 2027

Table 22. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2016-2021

Table 23. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2022-2027

Table 24. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2016-2021

Table 25. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2022-2027

Table 26. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2021

Table 27. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2022-2027

Table 28. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2016-2021

Table 29. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2022-2027

Table 30. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2021

Table 31. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2022-2027

Table 32. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2016-2021

Table 33. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2022-2027

Table 34. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2021

Table 35. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2022-2027

Table 36. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2016-2021

Table 37. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2022-2027

Table 38. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2021

Table 39. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2022-2027

Table 40. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2016-2021

Table 41. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2022-2027

Table 42. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2021

Table 43. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2022-2027

Table 44. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2016-2021

Table 45. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2022-2027

Table 46. Boehringer Ingelheim Corporate Summary

Table 47. Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 48. Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 49. Abbvie Corporate Summary

Table 50. Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 51. Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 52. Cipla Ltd Corporate Summary

Table 53. Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 54. Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 55. Hetero Drugs Limited Corporate Summary

Table 56. Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 57. Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 58. Pfizer Corporate Summary

Table 59. Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 60. Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 61. Novartis Corporate Summary

Table 62. Novartis Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 63. Novartis Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 64. Samsung Bioepis(Samsung Biologics) Corporate Summary

Table 65. Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 66. Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 67. Amgen Corporate Summary

Table 68. Amgen Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 69. Amgen Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 70. Celltrion Healthcare Corporate Summary

Table 71. Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 72. Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 73. Mylan Corporate Summary

Table 74. Mylan Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 75. Mylan Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 76. HETERO Corporate Summary

Table 77. HETERO Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 78. HETERO Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 79. Glenmark Pharmaceuticals Corporate Summary

Table 80. Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 81. Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 82. Emcure Pharmaceuticals Corporate Summary

Table 83. Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 84. Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars

Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 85. Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity (K Units) of Key Manufacturers in Global Market, 2019-2021 (K Units)

Table 86. Global Adalimumab, Infliximab And Etanercept Biosimilars Capacity Market Share of Key Manufacturers, 2019-2021

Table 87. Global Adalimumab, Infliximab And Etanercept Biosimilars Production by Region, 2016-2021 (K Units)

Table 88. Global Adalimumab, Infliximab And Etanercept Biosimilars Production by Region, 2022-2027 (K Units)

Table 89. Adalimumab, Infliximab And Etanercept Biosimilars Market Opportunities & Trends in Global Market

Table 90. Adalimumab, Infliximab And Etanercept Biosimilars Market Drivers in Global Market

Table 91. Adalimumab, Infliximab And Etanercept Biosimilars Market Restraints in Global Market

Table 92. Adalimumab, Infliximab And Etanercept Biosimilars Raw Materials

Table 93. Adalimumab, Infliximab And Etanercept Biosimilars Raw Materials Suppliers in Global Market

Table 94. Typical Adalimumab, Infliximab And Etanercept Biosimilars Downstream

Table 95. Adalimumab, Infliximab And Etanercept Biosimilars Downstream Clients in Global Market

Table 96. Adalimumab, Infliximab And Etanercept Biosimilars Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

Figure 1. Adalimumab, Infliximab And Etanercept Biosimilars Segment by Type

Figure 2. Adalimumab, Infliximab And Etanercept Biosimilars Segment by Application

Figure 3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market Overview: 2020

Figure 4. Key Caveats

Figure 5. Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size: 2021 VS 2027 (US\$, Mn)

Figure 6. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2016-2027 (US\$, Mn)

Figure 7. Adalimumab, Infliximab And Etanercept Biosimilars Sales in Global Market: 2016-2027 (K Units)

Figure 8. The Top 3 and 5 Players Market Share by Adalimumab, Infliximab And Etanercept Biosimilars Revenue in 2020

Figure 9. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2016-2027

Figure 10. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2016-2027

Figure 11. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (US\$/Unit), 2016-2027

Figure 12. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2016-2027

Figure 13. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2016-2027

Figure 14. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (US\$/Unit), 2016-2027

Figure 15. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2016-2027

Figure 16. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2016-2027

Figure 17. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2016-2027

Figure 18. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2016-2027

Figure 19. US Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 20. Canada Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 21. Mexico Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 22. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2016-2027

Figure 23. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2016-2027

Figure 24. Germany Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 25. France Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 26. U.K. Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 27. Italy Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 28. Russia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 29. Nordic Countries Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 30. Benelux Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 31. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2016-2027

Figure 32. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2016-2027

Figure 33. China Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 34. Japan Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 35. South Korea Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 36. Southeast Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 37. India Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 38. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2016-2027

Figure 39. By Country - South America Adalimumab, Infliximab And Etanercept

Biosimilars Sales Market Share, 2016-2027

Figure 40. Brazil Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 41. Argentina Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 42. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2016-2027

Figure 43. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2016-2027

Figure 44. Turkey Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 45. Israel Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 46. Saudi Arabia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 47. UAE Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2016-2027

Figure 48. Global Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity (K Units), 2016-2027

Figure 49. The Percentage of Production Adalimumab, Infliximab And Etanercept Biosimilars by Region, 2020 VS 2027

Figure 50. Adalimumab, Infliximab And Etanercept Biosimilars Industry Value Chain

Figure 51. Marketing Channels

I would like to order

Product name: Adalimumab, Infliximab And Etanercept Biosimilars Market - Global Outlook and Forecast 2021-2027

Product link: <https://marketpublishers.com/r/A015DBBC02F7EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A015DBBC02F7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

